Who are Neurocrine Biosciences's decision-makers?
Neurocrine Biosciences's official leadership and governance pages are the safest source for named executives.
- Primary buyers
- finance, procurement, IT, security, operations, legal, and the business owner tied to the active initiative
- Company status
- Public company; Nasdaq: NBIX
- HQ
- San Diego, CA
- Category
- Neuroscience-focused biopharmaceuticals
- Decision style
- Public-company buying committee
- Best source
- Official leadership or IR page
- Neurocrine Biosciences executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Neurocrine Biosciences finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Neurocrine Biosciences operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
Who leads Neurocrine Biosciences?
Neurocrine Biosciences's named leaders should be verified directly on the company's official leadership, governance, or investor-relations page. The profile intentionally avoids invented executive emails and treats official contact routes as the safe default.
Who owns buying decisions at Neurocrine Biosciences?
The buying committee depends on the offer. Finance and procurement usually control commercial approval, while IT, security, product, operations, legal, field, clinical, industrial, or commercial leaders shape requirements and vendor evaluation.
How should sellers map the account?
Start with headquarters and public leadership, then map functional owners by product area. Use filings, job posts, partner announcements, security pages, engineering posts, and investor materials to identify the active initiative behind a buying cycle.
As of June 2026.Sources:Neurocrine Biosciences official websiteNeurocrine Biosciences investor relations or company newsBuiltWith public technology profile
Neurocrine Biosciences — frequently asked questions
